Dandelion Science

Executive Summary

Dandelion Science, a Swiss biotech founded in 2021, is pioneering a novel approach to treating brain disorders through its Generative Neuromodulation™ platform. Unlike traditional therapies that target neurochemistry, the company leverages AI and machine learning to program the brain's network dynamics via non-invasive interventions. This paradigm shift aims to offer precise, personalized treatments for conditions such as depression, anxiety, and chronic pain. While still in early stages with no disclosed funding or clinical trials, the company's unique technology and focus on non-invasive neuromodulation position it as a potential disruptor in the neuroscience space. The lack of public milestones suggests significant funding rounds or proof-of-concept studies could be near-term catalysts.

Upcoming Catalysts (preview)

• H2 2026Seed or Series A funding round announcement60% success
• H1 2027Preclinical proof-of-concept data release40% success
• H2 2026Strategic partnership with academic or pharma collaborator50% success